INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Aardvark Therapeutics, Inc. (AARD) to Contact Law Firm

Moore Law, PLLC, a legal firm specializing in shareholder litigation based in New York, has launched an investigation into Aardvark Therapeutics, Inc. (NASDAQ: AARD) on behalf of its investors. The investigation aims to assess potential claims against the company’s officers and directors regarding the alleged overstatement of safety and efficacy related to their lead drug candidate, ARD-101. Specifically, it is claimed that Aardvark misrepresented the drug's safety profile, asserting minimal systemic exposure and no occurrence of serious adverse events.

The inquiry follows significant negative developments for Aardvark. On February 27, 2026, the firm announced a pause in its Phase 3 HERO trial upon discovering cardiac issues during a healthy-volunteer study. This revelation led to a sharp decline in the company’s stock price, dropping by approximately 56% from $12.49 to $5.47 per share by March 2, 2026. Additionally, on May 14, 2026, the FDA imposed a full clinical hold on ARD-101, causing further deterioration in stock value, which fell to $4.57 per share by May 15, a drop of about 32%.

Investors who have suffered losses due to these events are encouraged to contact Moore Law by emailing Fletcher Moore at fletcher@fmoorelaw.com. Shareholders may be eligible for monetary damages, governance reforms, and other forms of restitution without any out-of-pocket expenses, as all legal representation is provided on a contingency fee basis. For those interested in pursuing their claims, the contact information for Moore Law, located at 30 Wall Street, is provided for immediate outreach.

In light of the recent legal developments surrounding Aardvark Therapeutics, Inc. (NASDAQ: AARD), investors must carefully evaluate their positions and potential next steps. The notice from Moore Law PLLC highlights serious allegations against the company regarding the misrepresentation of the safety and efficacy of its lead drug candidate, ARD-101. Following a significant drop in stock value—over 56% after pausing a key clinical trial and an additional 32% following the FDA's clinical hold—shareholder confidence has been adversely affected.

For investors currently holding AARD shares, it's crucial to assess the implications of these developments. The law firm’s investigation suggests that the company's leadership may have overstated the prospects of ARD-101, leading to possible legal claims for damages. If such claims result in successful outcomes, they could yield monetary compensation or improvements in corporate governance—outcomes that could potentially stabilize the company's trajectory in the long run.

Investors should consider contacting Moore Law PLLC, as they offer representation on a contingency fee basis, meaning no upfront costs. This could provide a safer pathway for shareholders looking to recuperate their investments without significant financial risk.

Moreover, potential Aardvark investors must weigh the company's long-term viability against the backdrop of these legal challenges and safety concerns. While the clinical hold raises questions about ARD-101's future, it also opens the door to strategic purchasing opportunities for risk-tolerant investors. It may be prudent to monitor further developments, particularly regarding the outcome of the pending investigations, before making any significant investment decisions.

In conclusion, Aardvark Therapeutics currently presents a complex investment environment. Existing shareholders should explore legal avenues for recourse while prospective investors should closely monitor the company's response to these challenges.